Effect of Valeriana wallichii on alcohol addiction in mice
Anusua Biswas, Sugato Banerjee
Department of Pharmaceutical Science and Technology, Birla Institute of Technology, Ranchi, Jharkhand, India
|Date of Submission||16-Jul-2018|
|Date of Decision||05-Sep-2018|
|Date of Web Publication||17-Jan-2019|
Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi - 835 215, Jharkhand
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: Alcoholism is the most common form of addiction and a worldwide problem. Alcohol addiction primarily leads to alcohol dependence and on abstinence leads to withdrawal effects. Common pharmacological properties of compounds used against alcohol addiction include anti-anxiety, anticonvulsant, antidepressant, and nootropic actions. valeriana wallichii known ethnopharmacologically for its sleep-inducing effects have all the above-pharmacological properties. Aim: Here, we screen valeriana for possible anti-addictive potential. Materials and Methods: Effect of valeriana was measured on ethanol withdrawal anxiety using elevated plus maze. The role of valeriana on chronic ethanol consumption (21 days) was measured using two bottle choice method of voluntary drinking. We also measured the effect of the above herb on cortico-hippocampal gamma-aminobutyric acid (GABA) levels. Results: Valeriana was found to reduce ethanol withdrawal anxiety in a dose-dependent manner. The herb also decreased ethanol intake and increased water intake significantly (P < 0.001) after 4 days of administration. Both these effects were potentiated (P < 0.001) by GABAA agonist zolpidem, and not affected by N-Methyl D-aspartic acid antagonist memantine, suggesting the role of GABAA receptor. Chronic administration of valeriana (10 days) also significantly (P < 0.01) increased cortico-hippocampal GABA levels in mice. Conclusion: Thus, valeriana reduced both ethanol dependence and withdrawal in a GABAA-dependent manner showing promising anti-addictive potential.
Abbreviations Used: GABA: Gamma-aminobutyric acid; CNS: Central nervous system; CPP: Conditioned place preference; EPM: Elevated plus maze; NMDA: N-Methyl D-aspartic acid; HIV: Human Immunodeficiency virus.
Keywords: Addiction, alcohol, gamma-aminobutyric acid, Valeriana
|How to cite this article:|
Biswas A, Banerjee S. Effect of Valeriana wallichii on alcohol addiction in mice. Phcog Mag 2018;14:613-8
- Valeriana reduced ethanol withdrawal anxiety and showed anti-addictive property in a GABAA dependent manner.
| Introduction|| |
Alcoholism is the most common form of addiction and a worldwide problem. Alcoholism is the fifth leading risk factor for premature death and disability. Alcoholism may result in numerous disorders and injury-related medical problem. This includes cirrhosis of liver, liver cancers, Human Immunodeficiency Virus transmission, and physical injuries primarily traffic accidents and falls., Alcohol dependence is a multifactorial process that involves neurological, psychological and environmental factors. An individual usually gets addicted to alcohol consumption primarily due to alcohol's rewarding effects including euphoria and anti-anxiety potential and its noxious withdrawal effects including anxiety, muscle cramp, and depression. Relapses are primarily blamed toward withdrawal-anxiety, which reflects neurological changes because of continued alcohol exposure. Association of the above effects of alcohol with environmental clues may primarily determine alcohol intake. Alcohol withdrawal is associated with various unwanted effects such as agitation, sleep disturbances, anxiety, and increased sensitivity to pain, etc. Disulfiram, naltrexone, and acamprosate are US Food and Drug Administration (US-FDA) approved medications for the treatment of alcohol dependence. While Ibogaine is a drug with anti-addictive potential in animals is undergoing clinical trials. Ibogaine has shown serous cardiotoxicity; the other FDA approved compounds showed various adverse drug reactions including hepatotoxicity, psychosis, restlessness, constipation, optic neuritis, and are contraindicated in individuals with hepatic and cardiovascular complications. Thus, the commonly used drugs against alcohol addiction substantially affect the quality of life of the individual under anti-addictive therapy.
Compounds derived from natural sources have provided us with new lead molecules with high-therapeutic efficacy and low toxicity thus playing a major role in drug development. Valeriana wallichii is native to India, Nepal and China. This plant includes its rhizome part from which the active constituents are extracted. It has been traditionally used against insomnia, obesity, Central nervous system (CNS) disorders and also skin diseases. V. wallichii is widely known for its actions on CNS against anxiety, insomnia, epilepsy, antidepressant, and hysteria. Valerian contains valerianic oil (volatile oil) containing valerenic acid, isovaleric acid and terpineol. Valerinic acid, decreases the breakdown of gamma-aminobutyric acid (GABA) in the brain and act as GABAA receptor substrate resulting in its sedative and sleep-enhancing properties. Previous work suggests, CNS depressant action of Valeriana is due to the flavonoid glycosides such as hesperidin and linarin thus causing a general inhibition of neuronal activity. Flavone derivatives have shown GABAA receptor binding with benzodiazepine binding site which may be responsible for their depressant actions in mice. Valerian may inhibit α-ketoglutarate dehydrogenase and GABA transaminase thus preventing the breakdown of GABA and increasing its levels. It may also enhance the response of GABAA receptor and thus acts as GABAA agonist., Here, we report that acute administration of Valeriana may prevent ethanol withdrawal anxiety, whereas it's long-term administration may reduce ethanol intake in mice. Chronic administration of Valeriana extract led to change in cortico-hippocampal GABA levels, whereas GABAA agonist potentiated its anti-addictive properties. The, above results suggest that V. wallichii may prevent ethanol addiction in a GABAA-dependent manner.
| Materials and Methods|| |
Swiss albino mice (20–30 g) were used in this study. Animals were issued from the Institutional Animal House of Birla Institute of Technology, Mesra. All animals were kept in polyacrylic cages and maintained under standard conditions (room temperature 24°C–27°C and humidity 60%–65% with 12:12 light: dark cycles). The food was provided in the form of dry pellets and water ad libitum. The animals were allowed to get acclimatized to the laboratory conditions for 7 days before the commencement of the experiment. All experiments involving animals complied with the ethical standards of animal handling and approved by the Institutional Animal Ethics Committee (BIT/PH/IAEC/11/2016).
Estimation of blood alcohol levels
Blood was collected by retro-orbital bleeding with animals in light ether anesthesia after 20 min of ethanol administration. Ethanol levels were measured using ultraviolet (UV) assay kit (DRI ethyl alcohol assay) for alcohol estimation based on manufacturer's protocol (Thermo Fisher Scientific [India] Pvt. Ltd.).
Development of conditioned place preference model
The conditioned place preference (CPP) apparatus contain three compartments. The two compartments (30.5 cm × 26.5 cm × 37 cm) were connected by a central corridor (12.75 cm × 23 cm × 15.25 cm). The compartment on the left had black walls with a perforated stainless steel floor with round holes on staggered centers. The central corridor was transparent with a smooth floor, and the right compartment had white walls with a stainless-steel mesh floor.
CPP was performed as described Thanos et al.andLedesma et al., with slight modifications. It mainly consists of three phases:
- Preconditioning phase: (1st and 2nd day). The animals were placed in the middle chamber and allowed to explore both the chambers for 30 min
- Conditioning phase: (3rd–10th day). Each mouse was treated for eight consecutive sessions with the alternate oral administration of ethanol and saline. On days 3, 5, 7, and 9, the animals were administered ethanol (2 g/kg body weight; i.p. 10% [v/v]) and placed in one compartment for 30 min. Besides, on days 4, 6, 8, and 10, the animals were administered saline and placed in opposite compartment
- Postconditioning phase: (11th–12th day) Mice were placed in the middle chamber and allowed free access to both chambers for 30 min. Time spent in ethanol and saline-paired chamber was measured
- Treatment protocol: After the development of withdrawal symptoms (15th day after 3 days of abstinence from ethanol), the following treatment schedule was followed:
- Group 1: Saline
- Group 2: Ethanol
- Group 3: Ethanol abstinent + Tagara (Himalaya Drug Company; 50 mg/kg)
- Group 4: Ethanol abstinent + Tagara (100 mg/kg)
- Group 5: Ethanol abstinent + Tagara (100 mg/kg) + GABAA agonist
- Group 6: Ethanol abstinent + Diazepam (1 mg/kg)
- Group 7: Ethanol abstinent + Tagara (100 mg/kg) + N-Methyl D-aspartic acid (NMDA) antagonist.
The behavioral test (elevated plus maze test) was performed 60 min after oral drug administration and 30 min after i. p. administration.
Behavioral studies to measure ethanol withdrawal anxiety
Elevated plus maze
Elevated plus maze (EPM) was performed as described by Kokare et al. After drug treatment, individual mice were placed at the center of the maze, head facing an open arm. During the 5 min test period, the number of entries and time spent on the open arm were recorded automatically (Medicraft Electromedical, Lucknow, Uttar Pradesh, India).
Chronic-treatment study to measure ethanol intake
Two bottle choice ethanol drinking
We used the standard two-bottle choice protocol, which is a widely used animal model to capture aspects of voluntary ethanol consumption in humans. Following 7 days of acclimatization, animals were subjected to an ethanol drinking acquisition regimen. The animals remained in their home cages at all times throughout the study but had their water bottles removed during a 4 h and ethanol presentation period. During this time, animals were exposed to a free choice between ethanol (15% v/v) and water for 20 days but with no drug pretreatment.
After 20 days of ethanol administration, animals were divided into different groups for 10 days of treatment. Each day, the bottles were weighed before and after 4 h of limited access period and the differences were used to calculate the water and ethanol intake. The mean intake was expressed as g/kg body weight/day of water and g/kg body weight/day of ethanol intake. All animals were given unrestricted food access. Every 2 days, the bottles were switched to eliminate place preference. After 20 days of pretreatment with ethanol (15% v/v), the animals were divided into different treatment groups (n = 7 per group) as follows:
- Group 1: (control) received saline 30 days
- Group 2: received free choice ethanol (15% v/v)/water 30 days
- Group 3: received free choice ethanol (15% v/v)/water and Tagara (100 mg/kg) 21st–30th day
- Group 4: received free choice ethanol (15% v/v)/water and diazepam 21st–30th day
- Group 5: received free choice ethanol (15% v/v)/water, GABAA agonist and Tagara (100 mg/kg) 21st–30th day.
After the above experimental protocol of 30 days, five animals per group were sacrificed under ether anesthesia by cervical dislocation for biochemical estimation.
Estimation of gamma-aminobutyric acid levels in brain tissue
Brain tissue was homogenized in 5 mL of 0.01 M HCl. In this homogenate, 8 mL of ice cold ethanol was added and kept for 1 h at 0°C. The contents were centrifuged for 10 min at 16,000 rpm, and supernatant was collected in a petri dish. The precipitate was washed three times with 5 mL of 75% ethanol. The washes were combined with supernatant and evaporated to dryness. To the dry mass, 1 mL water and 2 mL chloroform were added and centrifuged at 2000 rpm. Upper phase containing GABA was separated, and 10 μL of it was applied as spot on Whatman filter paper. The mobile phase consisted of n-butanol, acetic acid, and water in 4:1:5 ratios. The chamber was saturated for half an hour with mobile phase. The paper chromatogram was developed with ascending technique. The paper was dried in a hot air oven and then sprayed with 0.5% ninhydrin solution in 95% ethanol. The paper was dried. Blue spot developed on paper, which was cut and heated with 2 mL ninhydrin solution on a water bath at 60°C–65°C. Water was added to the solution and kept for 1 h and supernatant was used. Absorbance was measured at 570 nm on a UV-visible spectrophotometer.
| Results|| |
Blood alcohol levels
Blood alcohol levels were measured by DRI Ethyl Alcohol Assay. This method is based on the high specificity of Alcohol Dehydrogenase for ethyl alcohol. The alcohol concentration in blood was found to be 40 mg/dl.
Conditioned place preference
The CPP test, consists of three phases-precondition, condition and postcondition. In precondition phase, the preference of animals was observed. Whereas, in condition phase, the animals were given the alternate dose of ethanol or saline in ethanol chamber and saline chamber respectively and finally postcondition phase was done on 11th day, where the animals were allowed to explore both the chambers freely and to make choice to spend more time in either of the environments provided to them. This environment provides a direct measure of the conditioned reinforcing effect of a drug. Animals were found to prefer the ethanol-paired chamber over the saline-paired chamber.
Ethanol CPP is illustrated in [Figure 1] on 11th day as total time spent in each chamber. There was a significant increase in time spent in the ethanol-paired chamber as compared to the saline-paired chamber as compared to the saline-paired chamber (P < 0.001) suggesting that the animals were addicted to ethanol.
|Figure 1: Condition place preference on ethanol administration. Time spent in alcohol and saline administration chamber on day 11 by control and ethanol-treated group. Ethanol-treated animals showed significant increase in (P < 0.001) time spent in ethanol-paired alcohol compared with saline-paired chamber. Values expressed as mean ± standard error of the mean n = 6|
Click here to view
Effect of valeriana on withdrawal anxiety
Ethanol withdrawal anxiety was measured by EPM test after 8 days of conditioning phase in which alternate dose of ethanol and saline was given for 10 days, followed by 5 days of abstinence. After 5 days of abstinence from ethanol (2 mg/kg b. w; i. p. 10% v/v, 8 days), animals showed significant decrease in time spent in the open arm of the EPM as compared to the control suggesting withdrawal anxiety. Administration of Valeriana (50 and 100 mg/kg) led to decrease in withdrawal anxiety as evidenced by the significant increase in time spent in the open arm of EPM. The above effect was found to be dose-dependent [Figure 2] and [Figure 5]b. Diazepam was used as a standard anxiolytic. The combination of valeriana + GABAA agonist, also showed significant (P < 0.001) anxiolytic action thus suggesting that anti-anxiety effect of valeriana may be mediated by GABAA receptors. However, NMDA antagonist memantine did not alter the effect of Valeriana alone [Figure 2].
|Figure 2: Effects of Valeriana on ethanol-withdrawal anxiety using elevated plus maze test. Ethanol abstinence significantly decreased (P < 0.01) time spend in open arm compared with ethanol-treated animals. Valeriana treatment to abstinent animals significantly (50 mg/kg, P < 0.001 and 100 mg/kg, P < 0.001) increased time spend in open arm compared with abstinent animals. Diazepam also significantly increased time spend in open arm over abstinent and ethanol-treated groups (P < 0.001). Animals treated with Valeriana in the presence of GABAA agonist spent significantly less time in the open arm (P < 0.001) compared with abstinent animals. Values expressed as mean ± standard error of the mean n = 6|
Click here to view
|Figure 5: Effect of Valeriana on water consumption (a) ethanol consumption patterns from day 2–30 (b) Ethanol consumption on day 24. There is a significant increase in water intake (P < 0.001) for Valeriana, Valeriana in combination with GABAA agonist and on diazepam treatment. Values expressed as mean ± standard error of the mean n = 6|
Click here to view
Effect of valeriana on GABA levels
Brain GABA level was estimated in cortical homogenates. The level of GABA in the cortical region significantly reduced after ethanol administration for 20 days. However, 10 days of treatment with Valeriana significantly increases the GABA levels in the cortical region and go it back to levels seen in normal animals [Figure 3].
|Figure 3: Effect of Valeriana on cortical GABA levels. Treatment with Valeriana significantly increased gamma-aminobutyric acid levels (P < 0.001). Values expressed as mean ± standard error of the mean n = 6|
Click here to view
Effect of valeriana on Ethanol intake
For the chronic study, two bottle choice ethanol drinking was used, and the study was conducted for 30 days. For the first 20 days, choices were between ethanol and water which was given freely to the animals i.e., 4 h of ethanol and rest of the time water was given. After that for the next 10 days treatment was given with Valeriana, Valeriana and GABA agonist (zolpidem) combination. Ethanol intake was found to increase till 20th day. From 24th day, there was a significant decrease in ethanol intake (P < 0.001) for animals treated with Valeriana, Valeriana in combination with GABAA agonist and diazepam groups when compared to ethanol-treated animals. The above results suggest that Valeriana prevented chronic ethanol intake while this effect may be mediated by GABAA receptors [Figure 4]a and [Figure 4]b. From 24th day water intake was also found to significantly increase (P < 0.001) in Valeriana, Valeriana in combination with GABAA agonist and diazepam treated animals [Figure 5]a and [Figure 5]b. Here, diazepam was used as standard drug. The above results confirm that valeriana may prevent chronic ethanol intake while this effect may be mediated by GABAA receptors.
|Figure 4: Effect of Valeriana on ethanol consumption (a) Ethanol consumption patterns from day 2–30 (b) Ethanol consumption on day 24. There was a significant decrease in ethanol intake (P < 0.001) after treatment with Valeriana alone or in combination with GABAA agonist and on diazepam treatment. Values expressed as mean ± standard error of the mean n = 6|
Click here to view
| Discussion|| |
In the present work, we studied the effect of Valeriana on withdrawal anxiety and chronic ethanol consumption in mice. The CPP results suggested that when given a free choice of environment after acute administration of ethanol (2.0 mg/kg b. w.; i. p., 10% v/v) on 11th day the animals preferred the ethanol-paired chamber to that of saline/water paired chamber thus showing ethanol addiction. The anxiolytic potential of Valeriana and diazepam was studied on acute ethanol withdrawal anxiety using EPM as a behavioral model of anxiety. Chronic ethanol consumption followed by withdrawal, results in abstinence syndrome., Alcohol withdrawal commonly results in anxiety disorders, which may be primarily responsible for reverting back to alcohol use. Ethanol may also be responsible for inter-receptor communication contributing to development of tolerance, dependence and withdrawal symptoms. During ethanol withdrawal, upregulation of NMDA receptors and a downregulation of GABAA receptors have been observed. In our study, valeriana reversed the withdrawal anxiety after ethanol abstinence in a dose-dependent manner as reveled by treated animals spending increased time in the open arm of the EPM compared to untreated ethanol-withdrawn animals. Valeric acid, from V. wallichii with GABA like property may also acts as NMDA-receptor antagonist. However, in our work, NMDA antagonist mamentine was unable to potentiate the effect of V. wallichii against ethanol withdrawal anxiety. The above result suggests the lack of involvement of NMDA receptors in anxiolytic effect of valeriana against ethanol withdrawal anxiety. However, zolpidem a GABAA agonist, potentiated the effect of valeriana thus suggesting the role GABAA receptors in valeriana mediated reduction in withdrawal anxiety. Valeric acid may also ameliorate various neuropsychiatric disorders. Valeric acid may inactivate α-ketoglutarate dehydrogenase resulting in increased GABA shunt activity which eventually increases GABA levels. It may also prevent the GABA transaminase function or act as GABAA receptor agonist. Downregulation of GABAA receptor and/or decrease in the GABAergic transmission may be responsible for ethanol withdrawal. The findings from the present investigation suggest that V. wallichii may reduce ethanol withdrawal anxiety in a GABAA-dependent manner. Long-term ethanol exposure may lead to altered neurotransmitter functions resulting in the development of alcohol dependence. Alcohol may inhibit NMDA receptors while prolonged ethanol intake may result in compensatory “upregulation” of this receptor functions. Previous studies have reported that ethanol alters the function of a number neurotransmitter receptors including GABAA. This imbalance between excitatory and inhibitory processes is primarily responsible for alcohol withdrawal symptoms. The upregulation of NMDA receptor functions after chronic ethanol intake is to sustain ethanol exposure. In our study after 30 days of chronic ethanol intake animals showed decreased cortical level of GABA. Evidences showed a decrease in GABAergic function after chronic administration of ethanol in experimental animals may be due to decrease in the GABAA receptor levels or altered receptor function. Valeriana treatment for 10 days after 20 days of ethanol treatment increased the GABA levels in cortex back to normal. In two bottle, choice model of voluntary drinking Valeriana treated animals showed a significant decrease in ethanol intake and a significant increase in water consumption as compared to control group from 24th day or after 4 days of therapy. The results were comparable with diazepam treated animals. Hence, Valeriana showed decreased withdrawal anxiety as well as decrease chronic ethanol intake, signifying its anti-addictive potential. The reduction in the chronic ethanol intake in Valeriana and Valeriana in combination with zolpidem-treated groups may also be a function of GABAergic system. Essential oil from V. wallichii may increase the levels of norepinephrine and serotonin responsible for its antidepressant actions. The study showed the involvement of the L-arginine-NO-cGMP pathway in the antidepressant-like effect of V. wallichii. It has also been shown to have analgesic property. While roots and rhizomes of V. wallichii contains valepotriates which may also facilitate GABA noradrenergic and/or dopaminergic transmission thus acting as an antidepressant. The above compounds with their respective physiological properties may also be responsible for anti-addictive potential of V. wallichii. Future studies should characterize specific phytoconstituents and define their molecular signaling responsible for the anti-addictive properties of Valeriana.
| Conclusion|| |
In the present study, we report anti-addictive activity of Valeriana against ethanol addiction in mice; it showed significant reduction in chronic ethanol intake as well as efficiently reduced withdrawal effects of ethanol in mice. The primarily mechanism responsible for both anti-addictive and anti-withdrawal effect of Valeriana was found to be GABA mediated.
We would like to acknowledge the Department of Pharmaceutical Sciences and Technology, BIT, Mesra, for providing the infrastructural support necessary to carry out the study.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Pallesen S, Lorvik IM, Bu EH, Molde H. An exploratory study investigating the effects of a treatment manual for video game addiction. Psychol Rep 2015;117:490-5.
Avena NM, Rada P, Hoebel BG. Evidence for sugar addiction: Behavioral and neurochemical effects of intermittent, excessive sugar intake. Neurosci Biobehav Rev 2008;32:20-39.
Vengeliene V, Bilbao A, Molander A, Spanagel R. Neuropharmacology of alcohol addiction. Br J Pharmacol 2008;154:299-315.
Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: A delicate relation. Molecules 2015;20:2208-28.
Johnston GA, Hanrahan JR, Chebib M, Duke RK, Mewett KN. Modulation of ionotropic GABA receptors by natural products of plant origin. Adv Pharmacol 2006;54:285-316.
Sah SP, Mathela CS, Chopra K. Antidepressant effect of Valeriana wallichii
patchouli alcohol chemotype in mice: Behavioural and biochemical evidence. J Ethnopharmacol 2011;135:197-200.
Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND. Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav Brain Res 2005;164:206-13.
Ledesma JC, Font L, Baliño P, Aragon CM. Modulation of ethanol-induced conditioned place preference in mice by 3-amino-1,2,4-triazole and D-penicillamine depends on ethanol dose and number of conditioning trials. Psychopharmacology (Berl) 2013;230:557-68.
Kokare DM, Chopde CT, Subhedar NK. Participation of alpha-melanocyte stimulating hormone in ethanol-induced anxiolysis and withdrawal anxiety in rats. Neuropharmacology 2006;51:536-45.
Li TK. Pharmacogenetics of responses to alcohol and genes that influence alcohol drinking. J Stud Alcohol 2000;61:5-12.
Marcucella H. Predicting the amount of ethanol consumed per bout from schedule of access
to ethanol. Anim Learn Behav 1989;17:101-2.
Condition Place Preference for Anxiety Study. Bio-protocol; Running Reward Condition Place Preference. Available from: https://bio-protocol.org/e3061
. [Last accessed on 2017 May 06].
Kliethermes CL. Anxiety-like behaviors following chronic ethanol exposure. Neurosci Biobehav Rev 2005;28:837.
Grochans E, Grzywacz A, Małecka I, Samochowiec A, Karakiewicz B, Samochowiec J, et al.
Research on associations between selected polymorphisms of genes DRD2, 5HTT, GRIK3, ADH4 and alcohol dependence syndrome. Psychiatr Pol 2011;45:325-35.
Nagy J. Alcohol related changes in regulation of NMDA receptor functions. Curr Neuropharmacol 2008;6:39-54.
Whittington MA, Lambert JD, Little HJ. Increased NMDA receptor and calcium channel activity underlying ethanol withdrawal hyperexcitability. Alcohol Alcohol 1995;30:105-14.
Toolika E, Ravi M, Bhat NP, Shetty SK, Ravishankar B, Savitha HP. A comparative pharmacological study on the effect of Tagara (Valeriana wallichii
) AND Jatamansi (Nardostachys jatamansi
) in the management of Anidra W.S.R to primary insomnia. J Phytopharmacol 2015;4:147-51.
Sachdeva A, Choudhary M, Chandra M. Alcohol withdrawal syndrome: Benzodiazepines and beyond. J Clin Diagn Res 2015;9:VE01-7.
Kuller LH, Lopez OL. Dementia: Is it time for a change in focus? Alzheimers Dement 2008;4:S77-84.
Luder AS, Parks JK, Frerman F, Parker WD Jr. Inactivation of beef brain alpha-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. Possible mechanism of anticonvulsant and toxic actions. J Clin Invest 1990;86:1574-81.
Monti B, Polazzi E, Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2009;2:95-109.
Frumkes TE, Nelson R. Functional role of GABA in cat retina: I. Effects of GABAA agonists. Vis Neurosci 1995;12:641-50.
Kim SG, Han BD, Park JM, Kim MJ, Stromberg MF. Effect of the combination of naltrexone and acamprosate on alcohol intake in mice. Psychiatry Clin Neurosci 2004;58:30-6.
Sah SP, Mathela CS, Chopra K. Involvement of nitric oxide (NO) signalling pathway in the antidepressant activity of essential oil of Valeriana wallichii
patchouli alcohol chemotype. Phytomedicine 2011;18:1269-75.
Sah SP, Mathela CS, Chopra K. Elucidation of possible mechanism of analgesic action of Valeriana wallichii
DC chemotype (patchouli alcohol) in experimental animal models. Indian J Exp Biol 2010;48:289-93.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
|This article has been cited by|
||Valeriana jatamansi Jones ex Roxb. Against Post-Traumatic Stress Disorder, Network Pharmacological Analysis, and In Vivo Evaluation
| ||Xue Yang, Jian-You Guo, Ya-Ni Jiang, Meng-Meng Liu, Qiu-Yu Li, Jia-Yuan Li, Xiao-Jia Wei, Guo-Hui Wan, Jin-Li Shi |
| ||Frontiers in Pharmacology. 2021; 12 |
|[Pubmed] | [DOI]|